Browsing Tag
GIST
1 post
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.
May 12, 2025